• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Rhythm Pharmaceuticals Inc.

    2/28/25 4:00:58 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RYTM alert in real time by email
    S-8 1 tmb-20250228xs8.htm S-8

    As filed with the Securities and Exchange Commission on February 28, 2025

    Registration No. 333-

    ​

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    ​

    Rhythm Pharmaceuticals, Inc.

    (Exact name of Registrant as specified in its charter)

    ​

    Delaware

       

    46-2159271

    (State or other jurisdiction of

    Incorporation or organization)

    ​

    (I.R.S. Employer

    Identification No.)

    ​

    222 Berkeley Street

    12th Floor

    Boston, MA 02116

    (857) 264-4280

    (Address of principal executive offices) (Zip code)

    ​

    Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan

    (Full title of the plan)

    ​

    David P. Meeker, M.D.

    Chief Executive Officer, President and Chairman of the Board

    Rhythm Pharmaceuticals, Inc.

    222 Berkeley Street

    12th Floor

    Boston, MA 02116

    (857) 264-4280

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

    ​

    With copies to:

    Peter N. Handrinos, Esq.

    Latham & Watkins LLP

    John Hancock Tower

    200 Clarendon Street

    Boston, MA 02116

    (617) 948-6060

    ​

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    ​

    Large accelerated filer ☒

    Accelerated filer ☐

     

     

    Non-accelerated filer ☐ 

    Smaller reporting company ☐

     

     

     

    Emerging growth company ☐ 

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for comply with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

    ​

    ​

    ​


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 2,495,626 shares of the Registrant’s common stock to be issued pursuant to the Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan (the “Incentive Plan”). A Registration Statement of the Registrant on Form S-8 relating to the Incentive Plan is effective.

    INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENTS ON FORM S-8

    The contents of the Registration Statements on Form S-8 (File Nos. 333-220925, 333-223647, 333-229642, 333-236829, 333-253709, 333-263168, 333-270231 and 333-277539), including any amendments thereto, filed with the Securities and Exchange Commission, relating to the Incentive Plan, are incorporated herein by reference.

    ​

    Item 8.

    Exhibits

    ​

    ​

    ​

    ​

    Exhibit
    Number

       

    Description

    ​

    ​

    ​

    4.1

     

    Amended and Restated Certificate of Incorporation of Rhythm Pharmaceuticals, Inc., dated October 10, 2017 (incorporated by reference to Exhibit 3.1 to Rhythm Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q (File No. 001-38223) filed on May 4, 2020)

    ​

    ​

    ​

    4.2

    ​

    Amended and Restated Certificate of Designations of Rhythm Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.4 to Rhythm Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q (File No. 001 38223) filed on May 7, 2024)

    ​

    ​

    ​

    4.3

     

    Amended and Restated Bylaws of Rhythm Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to Rhythm Pharmaceuticals, Inc.’s Current Report on Form 8-K (File No. 001-38223) filed on December 18, 2023)

     

     

    ​

    5.1*

     

    Opinion of Latham & Watkins LLP

     

     

    ​

    23.1*

     

    Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm

     

     

    ​

    23.2*

     

    Consent of Latham & Watkins LLP (included in Exhibit 5.1)

     

     

    ​

    24.1*

     

    Power of Attorney (included on signature page)

     

     

     

    99.1

     

    Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan and Form of Option Agreement (incorporated by reference to Exhibit 10.2 to Rhythm Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q (File No. 001-38223) filed on November 14, 2017)

     

     

     

    99.2

     

    2017 Equity Incentive Plan Form of Restricted Stock Unit Award Agreement (incorporated by reference to Exhibit 10.18 to Rhythm Pharmaceuticals, Inc.’s Annual Report on Form 10-K (File No. 001-38223) filed on March 2, 2020)

    ​

    ​

    ​

    99.3

    ​

    2017 Equity Incentive Plan Performance Unit Agreement (incorporated by reference to Exhibit 10.4 to Rhythm Pharmaceuticals, Inc.’s Quarterly Report on Form 10 Q (File No. 001 38223) filed on May 7, 2024)

     

     

     

    107.1*

     

    Filing Fee Table


    *

    Filed herewith.

    ​


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on February 28, 2025.

    RHYTHM PHARMACEUTICALS, INC.

     

    By:

    /s/ David P. Meeker, M.D.

     

    David P. Meeker, M.D.

     

    Chief Executive Officer, President and

     

    Chairman of the Board

    ​

    ​

    POWER OF ATTORNEY

    Each person whose signature appears below hereby constitutes and appoints David P. Meeker, M.D. and Hunter C. Smith, or each of them singly, with full power to act without the other, such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this registration statement and any and all amendments, including post-effective amendments to this registration statement, and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary or desirable to be done in connection therewith as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.


    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

    Signature

       

    Title

       

    Date

     

     

     

     

     

    /s/ David P. Meeker, M.D.

     

    Chief Executive Officer, President and Director

     

    February 28, 2025

    David P. Meeker, M.D.

     

    (Principal Executive Officer)

     

     

     

     

     

     

     

    /s/ Hunter C. Smith

     

    Chief Financial Officer

     

    February 28, 2025

    Hunter C. Smith

     

    (Principal Financial Officer)

     

     

     

     

     

     

     

    /s/ Christopher P. German

     

    Vice President, Corporate Controller

     

    February 28, 2025

    Christopher P. German

     

    (Principal Accounting Officer)

     

     

     

     

     

     

     

    /s/ Edward T. Mathers

     

    Lead Director

     

    February 28, 2025

    Edward T. Mathers

     

     

     

     

     

     

     

     

     

    /s/ Stuart Arbuckle

     

    Director

     

    February 28, 2025

    Stuart Arbuckle

     

     

     

     

     

     

     

     

     

    /s/ Camille L. Bedrosian, M.D.

     

    Director

     

    February 28, 2025

    Camille L. Bedrosian, M.D.

     

     

     

     

     

     

     

     

     

    /s/ Jennifer L. Good

     

    Director

     

    February 28, 2025

    Jennifer L. Good

     

     

     

     

     

     

     

     

     

    /s/ Christophe R. Jean

     

    Director

     

    February 28, 2025

    Christophe R. Jean

     

     

     

     

     

     

     

     

     

    /s/ David W. J. McGirr

     

    Director

     

    February 28, 2025

    David W. J. McGirr

     

     

     

     

     

     

     

     

     

    /s/ Lynn A. Tetrault, J.D.

     

    Director

     

    February 28, 2025

    Lynn A. Tetrault, J.D.

     

     

     

     

    ​


    Get the next $RYTM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RYTM

    DatePrice TargetRatingAnalyst
    11/25/2025$136.00Buy
    Citigroup
    11/5/2025Outperform → Perform
    Oppenheimer
    7/14/2025$130.00Mkt Perform → Mkt Outperform
    Citizens JMP
    7/10/2025$97.00Buy
    Goldman
    7/7/2025$88.00Outperform
    Leerink Partners
    4/7/2025$63.00Neutral → Buy
    BofA Securities
    3/5/2025$78.00Buy
    Stifel
    1/2/2025$80.00Buy
    Jefferies
    More analyst ratings

    $RYTM
    SEC Filings

    View All

    SEC Form 144 filed by Rhythm Pharmaceuticals Inc.

    144 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    2/5/26 4:30:28 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Rhythm Pharmaceuticals Inc.

    144 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    2/4/26 4:21:05 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Rhythm Pharmaceuticals Inc.

    SCHEDULE 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    1/30/26 2:43:31 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RYTM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Rhythm Pharmaceuticals with a new price target

    Citigroup initiated coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $136.00

    11/25/25 8:45:08 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rhythm Pharmaceuticals downgraded by Oppenheimer

    Oppenheimer downgraded Rhythm Pharmaceuticals from Outperform to Perform

    11/5/25 7:28:21 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rhythm Pharmaceuticals upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Rhythm Pharmaceuticals from Mkt Perform to Mkt Outperform and set a new price target of $130.00

    7/14/25 8:28:35 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RYTM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Smith Hunter C sold $702,744 worth of shares (6,628 units at $106.03), decreasing direct ownership by 5% to 125,537 units (SEC Form 4)

    4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

    2/6/26 6:38:19 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Head of International Mazabraud Yann converted options into 5,500 shares, increasing direct ownership by 15% to 43,155 units (SEC Form 4)

    4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

    2/3/26 4:38:11 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Smith Hunter C converted options into 26,000 shares and covered exercise/tax liability with 10,750 shares, increasing direct ownership by 13% to 132,165 units (SEC Form 4)

    4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

    2/3/26 4:36:15 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RYTM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit

    BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Hunter C. Smith, Chief Financial Officer, will participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 conference on Wednesday, February 11 at 11:00 a.m. ET in New York. The fireside chat will be webcasted and available under "Events & Presentations" in the Investor Relations section of the Company's website at www.rhythmtx.com. A replay of the webcast will be available on the Rhythm website for 30 days fol

    2/5/26 8:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones

    -- Q4 2025 preliminary net product revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 -- -- FY 2025 preliminary net product revenue of approximately $194 million, approximately 50% increase from FY2024 -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity -- -- On track to report topline data from 12-patient Japanese cohort of setmelanotide Phase 3 trial in acquired hypothalamic obesity in first quarter of 2026 -- -- On track to report topline data from Phase 3 EMANATE trial evaluating setmelanotide in genetically caused MC4R pathway diseases in first

    1/9/26 8:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

    -- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy -- -- Promising results supportive of Phase 3, registrational trial of setmelanotide in PWS -- -- Company initiated Phase 1, Part D study to evaluate weekly MC4R agonist RM-718 in patients with PWS -- -- Company to hold conference call on Thursday, December 11 at 8:00 a.m. -- BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today

    12/11/25 7:30:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RYTM
    Financials

    Live finance-specific insights

    View All

    Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

    -- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy -- -- Promising results supportive of Phase 3, registrational trial of setmelanotide in PWS -- -- Company initiated Phase 1, Part D study to evaluate weekly MC4R agonist RM-718 in patients with PWS -- -- Company to hold conference call on Thursday, December 11 at 8:00 a.m. -- BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today

    12/11/25 7:30:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

    BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast on Thursday, December 11 at 8:00 a.m. ET to disclose preliminary data from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS). Conference Call Information Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET on Thursday, December 11 to discuss this update. Participants may register for the conference call here. It is recommende

    12/10/25 4:01:00 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

    -- FDA sets updated PDUFA goal date of March 20, 2026 –  -- Company to hold conference today at 8:00 a.m. -- BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended by three months the review period for the supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide) for the treatment of acquired hypothalamic obesity. On Nov. 6, the FDA notified the Company that the Prescription Drug User Fee Act (PDUFA) goal date has been extended fr

    11/7/25 7:30:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RYTM
    Leadership Updates

    Live Leadership Updates

    View All

    Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer

    BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair "Al" Garfield, Ph.D. as Chief Scientific Officer, effective July 1. "We are excited to welcome Al back to Rhythm as we continue to leverage our understanding of the melanocortin-4 receptor (MC4R) pathway to bring potential therapies to patients and their families," said David Meeker, M.D., Rhythm Chairman, Chief Executive Officer and President. "Al's leadership and established scientific expertise and experience

    7/8/24 8:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

    BOSTON, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced the appointment of Dana Washburn, M.D., as Senior Vice President of Clinical Development and as a member of the Company's Executive Leadership Team, effective September 26, 2022. As SVP of Clinical Development, Dr. Washburn will lead the Company's robust clinical development program, clinical operations, and data management. "Dr. Washburn is a collaborative, resourceful leade

    10/6/22 4:02:00 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wren Appoints Bart Henderson as Chief Executive Officer

    Wren Therapeutics, a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, today announced the appointment of Bart Henderson as Chief Executive Officer. Wren's unique drug discovery platform harnesses advances in the biophysics of protein assembly dynamics to target the toxic fleeting protein intermediates, the oligomers, in neurodegenerative disease pathways, and discover small molecules that can block their generation with precision. Bart brings broad leadership experience in the biotechnology industry as a founder and co-founder of several companies including Torque (now Repertoire Immune Medicines), Rhythm (NASDAQ:RYTM) and its subsidiary Motus (acquired

    3/4/22 8:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RYTM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Rhythm Pharmaceuticals Inc.

    SC 13G - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    11/14/24 9:50:26 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rhythm Pharmaceuticals Inc.

    SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    11/14/24 5:46:11 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rhythm Pharmaceuticals Inc.

    SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    11/12/24 5:23:38 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care